The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥18 in Germany
Serotypes in PCV21 compared to PCV20 are associated with greater health and economic burden in Germany, primarily driven by the eight unique serotypes included in PCV21 and no other licensed vaccine. Including PCV21 in the national German vaccination guidelines may substantially reduce IPD-related health and economic burden among adults.
Authors
- Nicole Cossrow (ORCID: https://orcid.org/0009-0006-4982-4547)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Marion de Lepper (ORCID: https://orcid.org/0000-0003-2795-2039)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
- Muloongo Simuzingili (ORCID: https://orcid.org/0009-0003-3738-6189)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (Germany) (DE)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1080/14760584.2025.2606335
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00